Ping Bu

Title: Ping Bu: Innovative Inventor from Shanghai

Introduction

Ping Bu, based in Shanghai, China, is a notable inventor with a focus on pharmaceutical innovations. He holds two patents that contribute significantly to the field, particularly concerning the development of medical compounds.

Latest Patents

Ping Bu's latest patents include:

1. **Sulfuryl-substituted benzoheterocyclic derivative, preparation method and medical use thereof** - This patent details a sulfuryl-substituted benzoheterocyclic derivative, along with its preparation method and medical applications. The invention centers around a compound of formula (I) which may exist as a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug. The specifications outline definitions of each group within the formula.

2. **Azabicyclo derivatives, process for preparation thereof and medical use thereof** - This patent provides insights into azabicyclo derivatives, including a preparation process and their medical uses. Specific azabicyclo derivatives of formula (I) are noted for their potential as Epidermal Growth Factor Receptor (EGFR) inhibitors. The details regarding the variable R groups in the azabicyclo derivatives of formula (I) are thoroughly mapped out in the specifications.

Career Highlights

Throughout his career, Ping Bu has been associated with several prominent organizations, including Shanghai Haiyan Pharmaceutical Technology Co., Ltd. and Yangtze River Pharmaceutical Group Co., Ltd. His work in these companies reflects his dedication to pharmaceutical advancements.

Collaborations

Ping Bu has collaborated with notable coworkers in the industry, such as Yunzhou Jin and Fusheng Zhou. These partnerships have undoubtedly contributed to his innovative approaches and the successful development of his patents.

Conclusion

Ping Bu stands out as an influential inventor in the pharmaceutical sector. His contributions through his patents and collaborations highlight the ongoing innovation that is vital for advancing medical science. His work promises to lead to significant breakthroughs in treatment options, particularly concerning EGFR inhibitors and other therapeutic compounds.